Safety Tolerability and Effect on Opioid Use of Meloxicam IV Following Orthopedic Surgery

摘要

A Phase 3 randomized multicenter, double-blind, placebo-controlled trial ( ) compared once-daily intravenous (IV) meloxicam 30 mg to placebo, when added to the standard of care pain management regimens, in adults with moderate-to-severe pain following major elective surgery and concluded that meloxicam IV had a safety profile similar to placebo and reduced opioid consumption.